Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019

Brown, Patrick; Wieduwilt, Matthew J.; Logan, Aaron C.; DeAngelo, Daniel J.; Wang, Eunice S.; Fathi, Amir T.; Cassaday, Ryan D.; Litzow, Mark R.; Advani, Anjali S.; Aoun, Patricia; Bhatnagar, Bhavana; Boyer, Michael W.; Bryan, T.; Burke, Patrick W.; Coccia, Peter F.; Coutre, Steven; Jain, Nitin; Kirby, Suzanne; Liu, Arthur; Massaro, Stephanie A.; Mattison, Ryan J.; Oluwole, Olalekan O.; Papadantonakis, Nikolaos; Park, Jae; Rubnitz, Jeffrey E.; Uy, Geoffrey L.; Gregory, Kristina M.; Ogba, Ndiya; Shah, Bijal

doi:10.6004/jnccn.2019.0024

Cited by 49 publications

(45 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, for the sake of proof, a comparison of this regimen with the previously proposed drugs should be made. Similar studies have already been conducted regarding the use of topical antiseptic agents, recombinant keratinocyte growth factor (palifermin), and other means of preventing and treating of OM [6,7,8,9,10].…”

Section: Discussionmentioning

confidence: 80%

“…Given the nosological diversity and differences of cytostatic therapy of individual nosologies, we did not analyze the leukocyte formula in all patients studied. It should also be noted that granulocytemacrophage colony-stimulating factors were standardized to achieve 1.5x109/L leukocyte levels in all patients with neutropenia, as recommended by national and international protocols [6,17,20]. In the case of neutropenic fever, which was recorded in 27 out of 28 and 29 out of 30 patients of the respective groups, standardized antibacterial therapy was also prescribed [6,20], which did not affect the development and course of OM.…”

Section: Resultsmentioning

confidence: 99%

“…It should also be noted that granulocytemacrophage colony-stimulating factors were standardized to achieve 1.5x109/L leukocyte levels in all patients with neutropenia, as recommended by national and international protocols [6,17,20]. In the case of neutropenic fever, which was recorded in 27 out of 28 and 29 out of 30 patients of the respective groups, standardized antibacterial therapy was also prescribed [6,20], which did not affect the development and course of OM. This can be explained by the appearance of neutropenic fever 10-12 days after the start of cytostatic therapy, and histological signs of OM were recorded from the 7 day of therapy.…”

Section: Resultsmentioning

confidence: 99%

“…To date, the recommendations and guidelines for cytostatic treatment observed the actual absence of a consistent algorithm for the prevention and treatment of OM [6,20]. Among the remedies recommended for the prevention and treatment of OM include: caphosol, zinc sulfate, povidone iodide, palifermin as a topical cytostimulatory factor, cryotherapy, other local antiinflammatory drugs, vitamin complexes [5,13,14,15,19].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Pharmacological correction of various morphological forms of oral mucositis in patients with leukemia

et al. 2019

View full text Add to dashboard Cite

Oral mucositis (OM) is a common complication against the background of modern leukemia therapy, which significantly impairs patients’ quality of life. The purpose of the study was to evaluate the effectiveness of the use of local Cyanocobalamin and Decamethoxine therapy for the prevention and treatment of OM. The study was conducted on the basis of the hematology department of Vinnytsia Regional Clinical Hospital n.a. M.I. Pirogov in 2013-2019 (58 patients were studied with standard combination chemotherapy with Cytarabine, Methotrexate and anthracycline antibiotics). In addition to the standard clinical and laboratory study, dental examination was performed before treatment, at 7 and 14 days of treatment with determination of the degree of mucositis according to the NCI-CTC criteria and determination of quality of life indicators. At the same time, a sample incisional biopsy of the oral mucosa was performed with photo-fixation of histopreparations. In a group of 28 patients, 7 days orally administered a combination of Septefril (Decamethoxine) 0.2 mg 4-6 times daily, and Cyanocobalamin 500 mg 3 times daily. Statistical processing of the obtained results was carried out in the license package “STATISTICA 6.1” using non-parametric methods of evaluation of the obtained results. Prior to the onset of cytostatic therapy, no signs of inflammatory lesions were reported. However, patients with pre-established signs of caries, periodontal disease and lack of teeth subsequently experienced OM, even with the use of Cyanocobalamin and Septefril. Thus, after 7 days in 8 patients on the background of medication correction I-II degree of OM according to NCI-CTC was recorded, and only in 2 – III degree, unlike the group without correction. In the group where this combination of drugs was used, OM was recorded after 7 days in 12 patients, in contrast to the indices where the correction was not performed and the development of OM had a more pronounced course and was present in all patients. According to the morphological study, several degrees of OM were observed in patients. Initially, catarrhal stomatitis with pronounced plethora and swelling of the mucous membrane was detected. During the transition to the second stage of mucositis, the aphthous stomatitis was morphologically observed, as well as dead epithelial cells and the cells undergoing parakeratotic transformation. After the application of the proposed therapy, erosion remained after the film rejection, which recovered without scarring. Thus, cytostatic therapy in patients with leukemia always causes manifestations of OM, which are more pronounced in patients with concomitant risk factors. The use of a combination of Cyanocobalamin and Septefril significantly reduces the manifestation of OM and improves the quality of life of patients against cytostatic therapy.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacological correction of various morphological forms of oral mucositis in patients with leukemia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Risk stratification of patients with AML was primarily assessed according to European Leukemia Net (ELN) 2017 (14) and risk stratification of patients with ALL was primarily assessed according to the NCCN Guidelines (15). For patients with insufficient information for NCCN 2019 and ELN 2017, risk stratification was independently evaluated by two experienced hematologists, and results were recorded by consensus.…”

Section: Methodsmentioning

confidence: 99%

The value of <sup>18</sup>F‑FDG PET/CT in the prediction of clinical outcomes of patients with acute leukemia treated with allogeneic hematopoietic stem cell transplantation

et al. 2020

View full text Add to dashboard Cite

Silencing of IRF8 Mediated by m6A Modification Promotes the Progression of T‐Cell Acute Lymphoblastic Leukemia

Zhou

Xia

et al. 2022

Advanced Science

View full text Add to dashboard Cite

T‐cell acute lymphoblastic leukemia (T‐ALL) is an aggressive hematological malignancy with a poor prognosis, urging for novel therapeutic targets and treatment strategies. N6‐methyladenosine (m6A) is a crucial methylation modification that affects the pathogenesis of leukemia by regulating the mRNA of key genes. Interferon regulatory factor 8 (IRF8) is a crucial transcription factor for hematological lineage commitment, but its role in T‐ALL is unclear. Here, IRF8 is shown to suppress T‐ALL. The expression of IRF8 is abnormally silenced in patients with T‐ALL. Knockout of Irf8 significantly hastens the progression of Notch1‐induced T‐ALL in vivo. Overexpression of IRF8 suppresses the proliferation and invasion of T‐ALL cells by inhibiting the phosphatidylinositol 3‐kinase/AKT signaling pathway. The fat mass‐ and obesity‐associated protein (FTO), an m6A demethylase, is responsible for directly binding to m6A sites in 3′ untranslated region of IRF8 messenger RNA (mRNA) and inducing mRNA degradation via m6A modification. Targeting the FTO‐IRF8 axis is used as a proof of concept therapy; inhibition of FTO's demethylase activity drastically alleviates the proliferation of leukemic cells and prolongs the survival of T‐ALL mice by restoring IRF8 expression. This study elucidates the pathogenesis of T‐ALL from the perspective of epitranscriptomics and provides new insight into the genetic mechanisms and targeted therapy of T‐ALL.

show abstract

Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019

Cited by 49 publications

References 73 publications

Pharmacological correction of various morphological forms of oral mucositis in patients with leukemia

Pharmacological correction of various morphological forms of oral mucositis in patients with leukemia

The value of <sup>18</sup>F‑FDG PET/CT in the prediction of clinical outcomes of patients with acute leukemia treated with allogeneic hematopoietic stem cell transplantation

Silencing of IRF8 Mediated by m6A Modification Promotes the Progression of T‐Cell Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About